SGLT2 Inhibition: New Insight in Cardiology

Dear Colleagues,

Diabetes is an established risk factor of cardiovascular disease and predictor of poor outcome. This explain why achieving adequate management of diabetes and hyperlipidemia, is a corner stone in most cardiology patients’ treatment plan. SGLT-2 inhibitors showed proven benefits on improving outcome in heart failure patients, both systolic and diastolic, even these who are not diabetic. As well, SGLT-2 inhibitors are recommended in diabetic patients with established cardiovascular disease for primary prevention. This emerging role of SGLT-2 inhibitors on multiple cardiac conditions, suggests this topic of SGLT-2 inhibitors: a new insight in cardiology. 

Prof. Robert J. Chilton and Dr.  Badr Harfouch

Guest Editors

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.